This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

A method for determining a fertility period for a female human individual (FU), carried out in a device comprising a controller, a non-invasive heart sensor placed in contact or opposite to a portion of the skin of the individual, during the sleep of the individual, the heart sensor being configured to sense heart pulses of the individual and the controller being configured to determine the heart rate, the method comprising the following steps: /a/ collecting, at the sensor, heart pulses signals of the individual; /b/ extracting therefrom, at the controller, current heart rate during a night; /c/ calculating a minimal sleep heart rate denoted MSHR(i), over the night; /d/ comparing MSHR(i) with values of MSHR(k) recorded previously, and/or comparing MSHR(i) with a long term average of the minimal sleep heart rate values denoted LTHR; /e/ deducing therefrom a current ovulation probability index, according to a predefined criteria; /f/ if the ovulation probability index is higher than a predefined threshold denoted PTH, notify the individual with a fertility time window.

A method for determining a fertility period for a female human individual (FU), carried out in a device comprising a controller, a non-invasive heart sensor placed in contact or opposite to a portion of the skin of the individual, during the sleep of the individual, the heart sensor being configured to sense heart pulses of the individual and the controller being configured to determine the heart rate, the method comprising the following steps: /a/ collecting, at the sensor, heart pulses signals of the individual; /b/ extracting therefrom, at the controller, current heart rate during a night; /c/ calculating a minimal sleep heart rate denoted MSHR(i), over the night; /d/ comparing MSHR(i) with values of MSHR(k) recorded previously, and/or comparing MSHR(i) with a long term average of the minimal sleep heart rate values denoted LTHR; /e/ deducing therefrom a current ovulation probability index, according to a predefined criteria; /f/ if the ovulation probability index is higher than a predefined threshold denoted PTH, notify the individual with a fertility time window.

Methods, systems, and devices for miscarriage identification are described. A system may be configured to receive physiological data associated with a user that is pregnant and collected over a plurality of days, where the physiological data includes at least temperature data. Additionally, the system may be configured to determine a time series of temperature values. The system may then identify that the temperature values are lower than a pregnancy baseline of temperature values for the user and detect an indication of an early pregnancy loss of the user. The system may generate a message for display on a graphical user interface on a user device that indicates the indication of the early pregnancy loss.

A device usable directly in tumors with surface/subsurface angiogenesis wherein the tumor may be in cavities in the body for studying the micro circulation in other diseases for diagnostic use and to timely select the per patient therapy of choice. The device comprises a probe portion, a visualization portion, and a portion for sampling or intervention and a control station.

Methods and a system are provided for assessing postpartum hemorrhage risk and postpartum hemorrhage stages in a clinical setting. Generally, a clinician may indicate that the mass of several bloody items, indicated in type and quantity, is to be measured using a scale. The mass of bloody items is compared to the known unused dry mass of such items in order to accurately determine the quantitative blood loss (QBL) of a patient at the bedside. The cumulative QBL can be updated by weighing additional items. Based on the cumulative QBL, the patient's vital signs, and other factors, a corresponding hemorrhage stage is identified and communicated to the clinician. Recommendations specific to the hemorrhage stage are provided to a clinician. Some recommendations are selectable actions that trigger automatic placement of medical orders and notifications to relevant medical services, such as a blood bank or anesthesia.

The disclosed subject matter provides systems and methods for predicting a spontaneous preterm birth based on transvaginal ultrasound images of a subject. An example method can include providing a preterm birth prediction model, obtaining one or more transvaginal ultrasound images of the subject, each including cervical features, determining measurements of a plurality of cervical structure features from the one or more ultrasound images, assessing, using the preterm birth prediction model, cervical health of the subject based on the measurements of the plurality of cervical structure features, and calculating the spontaneous preterm birth risk based on the assessed cervical health, using the preterm birth prediction model.

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

A method of managing pain using neurophysiological data acquired from the brain of a subject is disclosed. The method comprises: identifying activity-related features in the data; parceling the data according to the activity-related features to define a plurality of capsules, each representing a spatiotemporal activity region in the brain; comparing at least some of the defined capsules to at least one reference capsule; and assessing the likelihood that the subject is experiencing pain responsively to the comparison.